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Staphylococcus aureus can stimulate activation and aggregation of platelets, which are thought to be
factors in the development of infective endocarditis. Previous studies have identified clumping factor A
(ClfA) and fibronectin binding proteins A and B (FnBPA and FnBPB) as potent platelet aggregators.
These proteins are able to stimulate rapid platelet aggregation by either a fibrinogen- or a fibronectin-
dependent process which also requires antibodies specific to each protein. Slower aggregation has been
seen in other systems where specific fibrinogen binding ligands are absent and platelet aggregation is
mediated by complement and specific antibodies. Bacteria expressing ClfB aggregate platelets with a
longer lag time than ClfA or FnBPA and FnBPB. In order to investigate whether ClfB causes platelet
aggregation in a complement- or fibrinogen-dependent manner, a non-fibrinogen-binding mutant of ClfB
(ClfB Q235A) was constructed. Lactococcus lactis expressing ClfB Q235A was able to stimulate platelet
aggregation in platelet-rich plasma without a significant increase in lag time. The requirements for
platelet aggregation were investigated using gel-filtered platelets. Fibrinogen and specific anti-ClfB an-
tibodies were found to be sufficient to allow platelet aggregation mediated by the wild-type ClfB protein.
It seems that ClfB causes platelet aggregation by a fibrinogen-dependent mechanism. The non-fibrinogen-
binding ClfB mutant was unable to stimulate platelet aggregation under these conditions. However,
bacteria expressing ClfB Q235A caused platelet aggregation in a complement-dependent manner which
required specific anti-ClfB antibodies.
Staphylococcus aureus is a commensal of the human anterior
nares which is commonly associated with nosocomial disease.
As well as causing superficial infections, S. aureus can cause
serious invasive conditions such as septic arthritis and infective
endocarditis (IE). IE is characterized by the buildup of vege-
tative bodies on heart valve surfaces which consist of bacteria
and platelet thrombi. It is though that the initial coaggregation
between bacteria and platelets can trigger activation of nearby
platelets, leading to thrombus formation. This condition is
caused predominantly by S. aureus and has a high mortality
rate. Treatment has become more difficult due to the recent
emergence of multidrug-resistant strains. Risk factors for in-
fection include rheumatic heart conditions and the use of pros-
thetic heart valves, although S. aureus can colonize previously
undamaged heart valves (21).
The ability to cause platelet aggregation is thought to con-
tribute to the development of IE (21, 27, 31). Several surface-
expressed proteins of S. aureus have been shown to stimulate
platelet activation and aggregation. These include the fibrino-
gen binding proteins clumping factor A (ClfA) and ClfB and
the bifunctional fibronectin-fibrinogen binding proteins A and
B (FnBPA and FnBPB) (11, 23). Thus, the interaction between
S. aureus and platelets is multifactorial.
Bacteria that cause platelet aggregation interact directly or
indirectly with receptors on the platelet surface. This initial
interaction results in the upregulation of the active form of
platelet integrin GPIIb/IIIa (10, 17). In its active form GPIIb/
IIIa can bind avidly to fibrinogen and fibronectin in solution (2,
3, 29). Subsequent aggregation occurs when neighboring plate-
lets interact via bound fibrinogen (21). Aggregation occurs
after a variable period of time referred to as the lag time. This
time reflects the time taken for activation and aggregation to
occur after the bacteria and platelets come into contact.
Bacteria expressing ClfA and FnBPA cause rapid aggrega-
tion with short lag times (1 to 2 min) (11, 18, 27). ClfA interacts
with platelets in a fibrinogen-dependent manner (11). The
initial adhesion between the bacterium and the resting form of
GPIIb/IIIa occurs via a fibrinogen bridge. Resting GPIIb/IIIa
is able to bind fibrinogen coating the bacterium, as it resembles
fibrinogen bound to a surface. One end of the bivalent fibrin-
ogen molecule is bound at the  chain by ClfA, while the other
 chain is free to interact with GPIIb/IIIa (9, 16, 18). Previous
studies have shown that the level of ClfA protein on the bac-
terial surface is crucial in this process. A “threshold” level of
protein expression is required for platelet activation to occur.
ClfA-specific antibodies are also required to interact with
platelet FcRIIa receptors which cluster to trigger activation
and intracellular signaling (18).
ClfA is expressed predominantly in the stationary phase of
growth and is the main mediator of platelet aggregation for
stationary-phase cells (18). In the exponential phase of growth,
rapid platelet activation is caused by FnBPA and FnBPB.
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FnBPA causes platelet aggregation in a manner similar to that
of ClfA (11). Fibrinogen bound by the A domain or fibronectin
bound by the BCD domains of the protein can interact with
GPIIb/IIIa on the surface of platelets. Specific antibodies to
FnBPA are also required to trigger activation and subsequent
aggregation (11).
Longer lag times to aggregation occur with bacteria lacking
potent proaggregatory surface components. Instead, a slower
process involving complement assembly coupled with specific
antibody binding is required for aggregation. Platelet aggrega-
tion mediated by Streptococcus sanguis requires complement
and immunoglobulin G (IgG) (12, 13). This was also found to
be the case for a non-fibrinogen-binding mutant of ClfA (ClfA
PY). Bacteria expressing ClfA PY caused platelet aggregation
in a complement-dependent manner with a longer lag time of
8 to 10 min. This suggests that assembly of complement pro-
teins and IgG binding are required to cross-link bacteria to a
platelet complement receptor and FcRIIa (18).
ClfB belongs to a family of surface expressed proteins known
as MSCRAMMs (microbial surface components recognizing
adhesive matrix molecules). It is most highly expressed in the
early exponential phase of growth (19). ClfB plays an impor-
tant role in nasal colonization by binding cytokeratin 10 in the
desquamated nasal epithelium (24, 33). Recent studies have
shown that immunizing mice with ClfB reduces nasal coloni-
zation (30). ClfB can also bind to fibrinogen, which is assumed
to be significant in platelet activation and aggregation. Unlike
ClfA, FnBPA, and FnBPB, which bind the  chain of fibrino-
gen, ClfB binds to the  chain (22, 25). This interaction is
presumed to occur by the “dock-lock-latch” mechanism in a
hydrophobic trench located between domains N2 and N3 of
the ClfB molecule (26) (Fig. 1).
Although ClfB is known to cause platelet aggregation and
has been shown to contribute to the pathogenesis of experi-
mental endocarditis in rats, little is known about the mecha-
nism by which platelet aggregation occurs (8, 23). Despite its
ability to bind fibrinogen, Lactococcus lactis expressing ClfB
caused aggregation with longer lag times (6 to 8 min) than
ClfA and FnBPA. The aims of this study were to establish
whether ClfB causes platelet aggregation by a fibrinogen- or
complement-dependent mechanism or by a combination of
both. The role of ClfB in platelet aggregation was studied in S.
aureus strain Newman and in a surrogate host, Lactococcus
lactis. In order to establish the role of fibrinogen in ClfB-
mediated aggregation, a non-fibrinogen-binding mutant of
ClfB was constructed. The involvement of individual plasma
proteins was studied using gel-filtered platelets (GFP).
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this
study are listed in Table 1. L. lactis was grown statically at 28°C in M17 (Difco)
agar or broth with 0.5% (wt/vol) glucose. S. aureus was grown on tryptic soy agar
or broth at 37°C with shaking (200 rpm). The following antibiotics (Sigma) were
added to the media as required: chloramphenicol at 10 g/ml, erythromycin at 10
g/ml, and tetracycline at 2 g/ml.
Staphylococcus aureus mutants. A deletion-substitution coagulase mutation
(coa::Tcr) was transduced into strains Newman, DU5999, and DU6009 by using
phage 85 (1). Transductants were validated by the coagulase tube test.
Construction of L. lactis(pNZ8037clfB). The clfB gene was amplified from
genomic DNA of S. aureus Newman by using the forward primer CTTGCCAT
GGAAAAAAGAATTGATTATTTGTCG and the reverse primer TGCTCTA
GATTCTTCCGGTAAAATGACTG. Following amplification, PCR products
were digested with NcoI and XbaI (sites are underlined) and ligated with
pNZ8037 plasmid digested with the same enzymes. Ligated DNA was electro-
porated into competent L. lactis cells (34).
Site-directed mutagenesis. The protein homology/analogy recognition engine
(PHYRE) was used to predict the three-dimensional structure of ClfB based on
other homologous proteins. Resulting structures were further analyzed using a
computer modeling program (Chimera) to select residues in the putative ligand
binding trench of ClfB. Mutagenesis of plasmid pNZ8037clfB was carried out
using the QuikChange protocol (Stratagene). Complementary forward (CATT
FIG. 1. Domain organization of ClfB. The signal sequence (S) is
followed by the ligand binding A domain, which is projected from the
cell surface by the repeat region (R). The C terminus consists of wall
(W), membrane (M), and cytoplasmic (C) spanning domains. The
LPETG motif is requited for cross-linking ClfB to the cell wall by
sortase.
TABLE 1. Bacterial strains and vectors
Strain or plasmid Relevant characteristics Referenceor source
L. lactis strain NZ9800 Host for expression plasmids; nisA 4
S. aureus strains
Newman Strain expressing high levels of ClfA and coagulase 7
DU5999 Newman clfA5; frameshift mutation in clfA 11
DU6000 Newman clfA5 clfB::lacZ (Emr); transduced clfB
mutation into DU5999
11
DU5854 Newman strain with coagulase mutation (coa::Tcr) 20
DU6016 Newman clfA5 coa; transduction of coa::Tcr into DU5999 This study
DU6017 Newman clfA5 coa::Tcr clfB::lacZ (Emr); transduction of
coa::Tcr into DU6000
This study
L. lactis plasmids
pNZ8037 Expression vector with nisin-inducible promoter (Cmr) 5
pNZ8037clfA pNZ8037 with full-length ClfA (Cmr) 18
pNZ8037clfB pNZ8037 with full-length ClfB (Cmr) This study
pNZ8037clfB Q235A pNZ8037 with full-length clfB Q235A This study
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TGACCCTAATGCAAGTGGTAACACATTTATGG) and reverse (CCATAA
ATGTGTTACCACTTGCATTAGGGTCAAATG) primers incorporating a
mutation (mutated nucleotides are in bold) were used to amplify the circular
template. The PCR products were digested with DpnI to eliminate parental
DNA and transformed into Escherichia coli XL-1Blue. Mutations were verified
by DNA sequencing. The PCR conditions used were as outlined by the
QuikChange protocol.
Fibrinogen binding assays. L. lactis strains were grown to stationary phase,
diluted 1/100 in fresh GM17, and allowed to reach exponential phase. Cultures
were induced with nisin and grown to stationary phase. Bacterial cells were then
washed twice in phosphate-buffered saline (PBS) and resuspended to an OD600
of 1. Cells were added to 96-well plates (Sarstedt) coated with 10 g/ml of
fibrinogen (Calbiochem). Crystal violet staining was used to measure adherent
bacteria (15).
Whole-cell immunoblots. L. lactis strains were grown and induced as described
above. Doubling dilutions of washed cells (5 l) were dotted onto a nitrocellulose
membrane (Protran). The membrane was blocked for 1 h with 10% (wt/vol) milk
powder (Marvel) in TS buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl) and then
probed with rabbit anti-ClfB polyclonal antibody (19). Bound antibody was
detected using goat anti-rabbit antibody conjugated to horseradish peroxidase
(HRP) (18).
Preparation of PRP. Platelet-rich plasma (PRP) was prepared as described
previously. Briefly, blood was drawn into a syringe containing 3.2% (wt/vol) Na
citrate. Whole blood was then centrifuged at 150 g for 10 min. The top platelet
layer was removed and the red blood cells centrifuged again to obtain platelet-
poor plasma (18).
Preparation of GFP. Blood was drawn into a syringe containing acid-citrate-
dextrose. Following preparation of PRP (as described above), the pH of the
platelets was adjusted to 6.5 and prostaglandin E1 (1 M) was added to prevent
activation during preparation of GFP. PRP was centrifuged at 720  g for 10
min. Platelets were resuspended in 1 ml of JNL buffer (6 mM dextrose, 130 mM
NaCl, 9 mM NaCl2, 10 mM Na citrate, 10 mM Tris, 3 mM KCl, 0.8 mM KH2PO4,
and 0.9 mM MgCl2 [pH 7.4]) and passed through a 10-ml Sepharose 2B column
(Sigma). The original volume of platelets was restored with JNL and supple-
mented with 2 mM CaCl2 (18).
Depletion of IgG from fibrinogen and human serum. Fibrinogen was purified
of contaminating IgG by passage through a column of protein A coupled to
Sepharose (Amersham Biosciences). The flowthrough was collected and concen-
trated back to the original volume in a centrifugal filter device (Amicon). Human
serum was depleted of IgG in the same manner. Enzyme-linked immunosorbent
assay were carried out to confirm that fibrinogen had been depleted of antibod-
ies, and serum samples were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis to confirm loss of IgG.
Depletion of ClfB-specific antibodies from pooled human IgG. Cultures of L.
lactis(pNZ8037) and L. lactis(pNZ8037clfB) induced with 3.2 ng/ml of nisin were
pelleted and washed in PBS. Cells were resuspended in 1 ml of pooled human
IgG (Gammmagard; Baxter) at 5% (wt/vol) and incubated with rotation at 4°C
for 1 h. Bacterial cells were pelleted, and the absorbed IgG was collected and
filtered using a 0.45-m filter (Sarstedt). Depletion of anti-ClfB antibodies was
confirmed by testing reactivity with recombinant ClfB by enzyme-linked immu-
nosorbent assay (28).
Inactivation of complement proteins in human serum. Human serum was
depleted of complement by heating at 56°C for 30 min or by treatment with
zymosan (100 mg/ml) as described previously (13).
Platelet aggregation. L. lactis cells were induced and grown to stationary phase
as described above. S. aureus cells were grown to mid-exponential phase. Cells
were washed twice with M17 broth or PBS and resuspended to an OD600 of 1.6.
Bacterial cells (25 l) were added to 225 l of PRP in glass cuvettes. PRP and
bacteria were incubated with stirring in an aggregometer (Bio-Data) for up to 25
min at 37°C, and light transmission was monitored. Aggregation was inhibited by
anti-GPIIb/IIIa (Abciximab, Eli Lily) antibodies at a 1/100 dilution and anti-
FcRIIa antibodies (IV3; kindly provided by R. Klimkowski, Medarex) at a 1/50
dilution. GFP were supplemented with purified fibrinogen at a final concentra-
tion of 0.5 mg/ml. Pooled IgG and depleted IgG were added to a final concen-
tration of 2 g/ml. Twenty-five microliters of human serum was added to a final
volume of 225 l GFP.
Statistical analysis. The data presented for this study represent the means
from three experiments  standard errors of the means unless otherwise
stated. The unpaired t test was used to determine the significance of differ-
ences in aggregation between strains, with significance defined as a P value of
0.05.
RESULTS
Contribution of ClfB to strain Newman-mediated platelet
aggregation. S. aureus strain Newman was selected for this
study because it does not have FnBPA and FnBPB attached to
its cell surface due to mutations that result in secretion of
truncated forms of each protein (14). It was therefore possible
to study the effect of ClfB expressed in the exponential phase
of growth without interference from the FnBPA and FnBPB
proteins. Strain Newman expresses high levels of coagulase,
which causes formation of fibrin clots in plasma. A coagulase-
defective mutation was therefore introduced into strains
DU5999 and DU6000 by transduction to prevent interference
in light transmission in the aggregometer caused by clot for-
mation.
Figure 2 shows a typical aggregation trace. Strains Newman
and DU5854 (Newman coa::Tcr) had equal lag times to ag-
gregation of approximately 3 min. Comparing strains DU5854
and DU6016 (Newman coa clfA5), an increase in lag time was
observed, from 3 to 4.67 min. This difference was found to be
statistically significant (P	 0.0123). Thus, the low level of ClfA
on exponential-phase cells contributes to aggregation.
Strain DU6017 (Newman coa clfA clfB) had a mean lag time
of 6.5 min in two of the donors tested. In the third donor no
aggregation occurred. When the 6.5-min lag time was com-
pared to the lag time caused by strain DU6016, the difference
was statistically significant (P 	 0.0191). These data show that
both ClfA and ClfB play a role in the ability of S. aureus from
the exponential phase of growth to interact with platelets.
Controlled expression of ClfB from L. lactis. In order to
express ClfB on the surface of L. lactis cells in a controlled
fashion, the clfB gene was cloned into the nisin-inducible
pNZ8037 vector. Whole-cell immunoblotting was carried out
to study ClfB protein expression by L. lactis(pNZ8037clfB),
using nisin concentrations ranging from 0.025 ng/ml to 3.2
ng/ml. A constant number of cells were dotted onto a nitro-
cellulose membrane and probed with anti-ClfB antibodies. An
approximate 64-fold increase in ClfB expression was seen in
cells induced with 3.2 ng/ml nisin compared to uninduced cells
(Fig. 3A).
The ability of L. lactis expressing ClfB (L. lactis ClfB) to
adhere to immobilized fibrinogen was assessed. L. lactis ClfB,
L. lactis ClfA, and a strain containing the empty pNZ8037
FIG. 2. Representative aggregation trace. Strains Newman, DU5854
(Newman coa), DU6016 (Newman coa clfA), and DU6017 (Newman coa
clfA clfB) were grown to exponential phase, washed, and added to PRP in
an aggregometer.
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vector were induced with increasing nisin concentrations, and
their abilities to bind to microtiter wells coated with fibrinogen
were compared. Increasing the level of ClfB on the cell surface
correlated with a sharp increase in fibrinogen binding up to
nisin concentrations of 0.4 ng/ml. Increasing the inducer con-
centration above this level did not increase adherence to fi-
brinogen. L. lactis ClfB adhered to fibrinogen less avidly than
L. lactis ClfA across the range of inducer concentrations used
(Fig. 3B). This could be due to a lower level of ClfB expression
compared to ClfA or to a lower affinity for fibrinogen. L.
lactis(pNZ8037) did not bind detectably to fibrinogen.
Threshold level of ClfB necessary for platelet activation and
aggregation. Previous studies have shown that a minimum level
of ClfA is required for platelet activation and aggregation
to occur (18). To test the level of ClfB required, L.
lactis(pNZ8037clfB) was induced with increasing concentra-
tions of nisin. Induced cells were added to PRP, and the lag
time to aggregation was measured. It was found that 0.2 ng/ml
of nisin was sufficient to cause platelet aggregation. Below this
level of inducer, no aggregation was seen (Fig. 4A). The cells
induced with the highest nisin concentrations produced the
shortest lag times (6.7 min at 3.2 ng/ml nisin, compared to 11.7
min at 0.2 ng/ml nisin [P  0.01]). These results indicate that
the lag time to aggregation is dependent on the level of ClfB
protein expressed on the bacterial cell surface. There seems to
be a decrease in total percent aggregation caused by cells
induced with lower levels of nisin (0.2 and 0.4 ng/ml) compared
to fully induced cells (78%). This trend was not statistically
significant, although this would probably change if a larger
number of samples were tested.
FIG. 3. Expression of ClfB from L. lactis and fibrinogen binding. (A) Whole-cell immunoblot detecting ClfB expression. Doubling dilutions of
bacterial cells induced with nisin from 0 to 3.2 ng/ml were dotted onto nitrocellulose membranes. The membranes were probed with rabbit
anti-ClfB antibody, and bound antibody was detected using goat anti-rabbit antibody conjugated to HRP. (B) L. lactis ClfA, L. lactis ClfB, and L.
lactis(pNZ8037) were induced with nisin at from 0 to 3.2 ng/ml and grown to stationary phase. Adherence of the cells to immobilized fibrinogen
was assessed by crystal violet staining.
FIG. 4. (A) Threshold level of ClfB expression required for platelet activation. L. lactis ClfB cultures induced with increasing concentrations
of nisin were incubated with PRP, and the lag time to activation was measured. (B) Threshold level of bacterial cells required for platelet activation.
Doubling dilutions of fully induced L. lactis ClfB (OD600 of 1.6) were added to platelets, and the lag time to activation was measured. Asterisks
indicate no activation after 25 min. The percent aggregation is shown above the error bars.
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Experiments were also carried out to determine the thresh-
old number of bacterial cells necessary to cause ClfB-mediated
aggregation. Doubling dilutions of fully induced L. lactis ClfB
(OD600 of 1.6) were added to platelets. It was found that an
OD600 of 0.8 was necessary to cause platelet aggregation (Fig.
4B). The lag time to aggregation increased from 8 min at an
OD600 of 1.6 to 14 min at an OD600 of 0.8 (P 	 0.0061). (Fig.
4B). In contrast, when 20 M ADP was added to platelets,
aggregation occurred immediately and reached 82% (data not
shown).
Inhibition of aggregation by anti-GPIIb/IIa and anti-FcRIIa
antibodies. Antibodies to platelet receptors GPIIb/IIIa and
FcRIIa were used to inhibit ClfB-mediated aggregation. Anti-
GPIIB/IIIa reduced aggregation from 69% to 4% (Fig. 5).
Anti-FcRIIa reduced aggregation from 69% to 2%, showing
that both receptors are absolutely required in ClfB-mediated
platelet aggregation.
Non-fibrinogen-binding mutant of ClfB. A three-dimen-
sional molecular model of domains N2 and N3 of ClfB was
constructed based on the known structures of ClfA and SdrG.
The structures were analyzed to select residues in the putative
ligand binding trench of ClfB that could play a role in ligand
binding. Thus, amino acid residue Q235 was selected for mu-
tagenesis. The pNZ0837clfB plasmid was used as a template
for mutagenesis, and ClfB Q235A was expressed on L. lactis.
The abilities of L. lactis expressing wild-type ClfB and ClfB
Q235A to adhere to immobilized fibrinogen were compared.
ClfB Q235A showed a dramatic decrease in adherence to fi-
brinogen (Fig. 6A). Whole-cell immunoblotting was carried
out to compare the expression of wild-type ClfB and ClfB
FIG. 5. Inhibition of platelet aggregation using anti-GPIIb/IIIa and
anti-FcRIIa antibodies. PRP was incubated with the inhibitory anti-
bodies for 15 min at 37°C prior to the addition of L. lactis ClfB.
FIG. 6. (A) Fibrinogen binding abilities of L. lactis ClfB and L. lactis ClfB Q235A. L. lactis ClfB, L. lactis ClfB Q235A, and L. lactis (pNZ8037)
were induced with increasing nisin concentrations and grown to stationary phase. Adherence of washed cultures to 10 g/ml of fibrinogen was
assessed by crystal violet staining. (B) Expression of ClfB and ClfB Q235A from L. lactis. Expression of ClfB Q235A from L. lactis was compared
to that of wild-type ClfB. Doubling dilutions of bacterial cells induced with nisin at from 0 to 3.2 ng/ml were dotted onto nitrocellulose membranes.
The membranes were probed with rabbit anti-ClfB antibody, and bound antibody was detected using goat anti-rabbit antibody conjugated to HRP.
(C) Western immunoblot of protoplasts of L. lactis, L. lactis ClfB, and L. lactis ClfB Q235A.
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Q235A on L. lactis at different concentrations of the inducer
nisin. There was no noticeable difference in the levels of ex-
pression detected with rabbit anti-ClfB antibody (Fig. 6B).
Whole-cell immunoblotting was also carried out with pooled
human IgG which contains anti-ClfB antibodies. No difference
was detected in IgG binding between L. lactis expressing ClfB
and ClfB Q235A. This strongly suggests that the proteins were
expressed at the same level (data not shown). Western immu-
noblotting showed that ClfB and ClfB Q235A migrated as
bands of 150 kDa, which shows that the mutant protein is
intact (Fig. 6C).
Fibrinogen and ClfB-specific antibodies are required for
ClfB-mediated platelet activation and aggregation. The lag
times and percent aggregation in PRP were very similar for L.
lactis ClfB and L. lactis ClfB Q235A. L. lactis ClfB caused
aggregation after a lag time of 5.7 min, compared to 6 min for
L. lactis ClfB Q235A. The percent aggregation was slightly
lower for L. lactis ClfB Q235A (70.3%, compared to 80.3% for
L. lactis ClfB wild type), but this was not found to be statisti-
cally significant (P 	 0.1621) (Fig. 7).
To determine which plasma proteins were required for ClfB-
mediated platelet activation, studies were performed with
GFP. When fibrinogen alone was added to GFP, no activation
occurred. The further addition of pooled human antibodies
restored the ability of L. lactis ClfB to cause platelet aggrega-
tion. However, fibrinogen and pooled IgG were not able to
restore the ability of ClfB Q235A to aggregate platelets, which
indicates that additional plasma proteins are required (Fig. 7).
In order to determine if anti-ClfB antibodies in pooled hu-
man IgG were required to stimulate platelet activation, the
IgG was absorbed with fully induced L. lactis(pNZ8037clfB)
and L. lactis(pNZ8037) cells. When IgG was depleted of spe-
cific ClfB antibodies, aggregation by L. lactis ClfB was reduced
to 18.7%. IgG absorbed with L. lactis(pNZ8037) still supported
activation and subsequent aggregation (Fig. 7).
Complement fixation is required for platelet aggregation
mediated by ClfB Q235A. L. lactis ClfB Q235A was unable to
cause platelet activation in GFP supplemented with fibrinogen
and pooled antibody (Fig. 7). Upon the addition of serum and
fibrinogen (required for aggregation following activation) to
GFP, the non-fibrinogen-binding mutant was able to cause
aggregation (Fig. 8). The apparent difference in percent aggre-
gation caused by the mutant and wild-type proteins (49% com-
pared to 62%, respectively) was not statistically significant (P 	
0.7325). Serum was treated with zymosan or heated at 56°C for
30 min to inactivate complement. In both cases activation by L.
lactis ClfB was not affected, whereas L. lactis ClfB Q235A did
not stimulate activation. This shows that the non-fibrinogen-
binding mutant of ClfB could promote platelet activation only
by a complement-dependent mechanism (Fig. 8).
Specific anti-ClfB antibody is required for platelet aggrega-
tion mediated by ClfB Q235A. In order to determine if anti-
ClfB antibodies were required for L. lactis ClfB Q235A-medi-
ated aggregation, serum was depleted of IgG by absorption
with protein A-Sepharose. Serum depleted of IgG did not
support platelet activation (P 	 0.0001). Addition of pooled
human IgG restored the ability of ClfB Q235A to cause acti-
vation (62% aggregation), as did the addition of pooled human
IgG absorbed with L. lactis(pNZ8037). When pooled human
IgG absorbed with L. lactis(pNZ8037clfB) was added to IgG-
depleted serum, aggregation was reduced to 19% (P	 0.0080).
Thus, specific anti-ClfB antibodies are required for L. lactis
ClfB Q235A-promoted activation of platelets (Fig. 9).
DISCUSSION
Several surface proteins of S. aureus have been shown to be
involved in the process of platelet activation and aggregation.
A common mechanism for activation by ClfA and FnBPA
involves an initial interaction between the bacterium and the
platelet receptor GPIIb/IIIa. Bound fibrinogen and fibronectin
coat the bacterial surface and cross-link the bacterium to
FIG. 7. Activation of GFP. L. lactis(pNZ8037), L. lactis ClfB, and
L. lactis ClfB Q235A were added to GFP supplemented with fibrino-
gen, pooled antibodies, and pooled antibodies absorbed with L. lactis-
(pNZ8037) or L. lactis ClfB. Percent aggregation was recorded after
25 min.
FIG. 8. Role of complement proteins in aggregation mediated by
ClfB and ClfB Q235A. L. lactis ClfB and L. lactis ClfB Q235A were
added to GFP to which fibrinogen and serum, serum treated with
zymosan, or serum heated at 56°C was added.
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GPIIb/IIIa on the platelet surface. The abilities of ClfA to bind
avidly to fibrinogen and of FnBPA to bind both fibrinogen and
fibronectin allow for short lag times to aggregation (11, 18).
When specific binding proteins are absent, extended lag times
for aggregation are seen, such as were described for the non-
fibrinogen-binding mutant of ClfA and for platelet aggregation
mediated by Streptococcus sanguis (13, 18). These longer lag
times are reflective of the time taken for complement assembly
to occur on the bacterial surface. ClfB is known to bind to the
 chain of fibrinogen. It was therefore surprising that longer
lag times to aggregation (6 min) were caused by L. lactis ex-
pressing ClfB. The mean lag time was marginally shorter than
that of the non-fibrinogen-binding mutant of ClfA (8 to 10
min) (18).
The results of this study show that ClfB expressed from L.
lactis can cause activation and aggregation of platelets in a
fibrinogen-dependent manner, although binding fibrinogen
alone is not sufficient to stimulate activation. When GFP were
supplemented with fibrinogen and pooled human IgG, L. lactis
ClfB was able to stimulate platelet aggregation with a lag time
of approximately 6 min. Further experiments showed that anti-
ClfB antibodies present in pooled human IgG were necessary
for activation to occur (Fig. 7). It seems that ClfB is able to
cause platelet aggregation in the same manner as ClfA and
FnBPA. Bound fibrinogen acts as a bridge between the platelet
and the bacterium, while specific anti-ClfB antibody can bind
the Fc receptor on platelets to cause activation through recep-
tor clustering and intracellular signaling. The fact that inhibi-
tors of GPIIb/IIIa (Abciximab) and FcRIIa (IV3) prevented
aggregation mediated by L. lactis ClfB confirms the role of
these receptors in the interaction between platelets and bac-
teria expressing ClfB (Fig. 5).
Since ClfB can cause aggregation in a fibrinogen-dependent
manner, it seems strange that the lag time to aggregation is
longer than that seen for ClfA and other fibrinogen binding
molecules (11, 18). There are several possibilities to explain
this difference. Fibrinogen is a symmetrical molecule consisting
of two  chains, two  chains, and two 
 chains (16). Unlike
ClfA, FnBPA, and FnBPB, ClfB binds the  chain of fibrino-
gen in a flexible region located between residues 240 and 410
(32). In the case of ClfA and the FnBPs, the interaction with
platelets occurs via a fibrinogen molecule bound at the  chain
protruding from the end of domain D by GPIIb/IIIa and ClfA.
This may orient fibrinogen in a manner that is more suitable
for binding GPIIb/IIIa than when it is bound at the  chain
(Fig. 10).
The affinities of ClfB and ClfA for fibrinogen have not been
compared directly, and it is possible that ClfB binds with a
lower affinity. The  chain of fibrinogen has also been shown to
be susceptible to cleavage by proteases (6, 32). These two
possibilities would also explain the difference seen between L.
lactis ClfB and L. lactis ClfA in fibrinogen binding assays.
Across the range of inducer concentrations tested, cells ex-
pressing ClfB bound at consistently lower levels than cells
expressing ClfA (Fig. 3). Any of these factors could contribute
to the longer lag time to aggregation caused by ClfB.
Platelet activation and aggregation mediated by ClfB re-
quire a minimum level of ClfB protein to be expressed on the
surface of cells. The threshold for platelet activation stimu-
lated by L. lactis ClfB occurred at 0.2 ng/ml of nisin (Fig. 4A).
Below this level, no activation was be seen. Increasing the
FIG. 9. Requirement for specific ClfB antibodies in ClfB Q235A-
mediated platelet activation. Serum depleted of IgG was added to GFP
supplemented with fibrinogen. Pooled IgG and absorbed IgG were
added to samples.
FIG. 10. (A) Fibrinogen-dependent platelet aggregation by ClfA. ClfA requires both fibrinogen and IgG to interact with GPIIb/IIIa and
FcRIIa platelet receptors. Both GPIIb/IIIa and ClfA bind the  chain of fibrinogen. (B) Fibrinogen-dependent platelet aggregation by ClfB. ClfB
requires fibrinogen and IgG to cause platelet activation. ClfB interacts with the  chain of fibrinogen, while GPIIb/IIIa binds the  chain.
(C) Complement-dependent platelet activation mediated by ClfB Q235A. Assembly of complement proteins and IgG binding are required to
engage the platelet complement receptor and FcRIIa, respectively.
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number of ClfB molecules on the surface of the cell decreases
the lag time to aggregation. The initial adhesion of bacteria to
platelets via fibrinogen seems to be important in determining
the lag time. Similar results have been seen with bacteria ex-
pressing ClfA (18). This study also found that a threshold
number of bacterial cells are needed to cause platelet activa-
tion. At lower concentrations of bacteria, the lag time to acti-
vation increased. Decreasing the level of ClfB on the surface of
L. lactis seemed to decrease percent aggregation, although the
difference was not statistically significant.
Bacteria expressing the non-fibrinogen-binding mutant ClfB
Q235A were still able to cause aggregation in PRP. The lag
time to aggregation was not significantly different from that
caused by the wild-type protein. However, experiments carried
out with GFP demonstrated that ClfB Q235A did not cause
aggregation in a fibrinogen-dependent manner. Instead, aggre-
gation was dependent on the presence of complement. When
serum was heated to inactivate complement and added to
GFP, only cells expressing the wild-type ClfB protein could
cause aggregation. The same result was seen with zymosan-
treated serum (Fig. 8). Platelet aggregation could be restored
by adding pooled IgG or IgG absorbed against L. lactis(pNZ8037).
Adding IgG absorbed against L. lactis(pNZ8037clfB) did not
restore activation (Fig. 9). We can therefore conclude that
specific anti-ClfB antibodies are required for L. lactis ClfB
Q235A-mediated platelet activation and aggregation. These
results suggest that ClfB Q235A causes aggregation in the
same way as the non-fibrinogen-binding mutant of ClfA (ClfA
PY). Complement proteins bound to the bacterium can pre-
sumably interact with a complement receptor on the surface of
the platelets. Bound anti-ClfB antibodies form another link to
the platelet via the FcRIIa receptor. The fact that the fibrin-
ogen- and complement-dependent mechanisms of platelet ag-
gregation identified in this study have similar lag times suggests
that both mechanisms can contribute to overall activation and
aggregation caused by ClfB.
This study also investigated the role that ClfB plays in plate-
let aggregation mediated by S. aureus strain Newman. This
strain produces a high level of coagulase, which caused fibrin
clot formation when cells were incubated with PRP for long
periods of time. For this reason a coagulase-defective mutant
of strain Newman (DU5854) was used. Strain DU5854 had the
same lag time as wild-type Newman (approximately 3 min).
Eliminating ClfA increased the lag time from 3 min to 4.67
min. Normally, in the exponential phase of growth bacterial
cells express high levels of FnBPA and FnBPB, which cause
rapid aggregation (11). However, Newman is defective in
FnBP expression (14). ClfA is expressed predominantly in the
stationary phase of growth. Previous studies using stationary-
phase cells have shown that ClfA causes rapid activation with
a lag time of 1 min (18). ClfA is not expressed at high levels on
exponential-phase cells, and therefore an extended lag time
was seen in this study.
ClfB contributes to platelet activation and aggregation by
exponentially growing cells. Strain DU6017 lacks both ClfA
and ClfB. In two of the donors tested, DU6017 activated plate-
lets with an average lag time of 6.5 min, compared to the
4.67-min lag times caused by DU6016. In the third donor,
DU6017 failed to activate platelets. This suggests that variable
host factors, such as antibody levels and the presence of plate-
let receptors, contribute to the ability of bacteria expressing
ClfB to cause activation. Overall, the presence of ClfB on S.
aureus did shorten the lag time to aggregation. We propose
that ClfB can contribute to and amplify the platelet aggrega-
tion caused by FnBPA and FnBPB in the exponential phase of
growth.
In conclusion, this study found that ClfB expressed on the
surface of bacteria can aggregate platelets in a fibrinogen-
dependent manner. Bacteria expressing a non-fibrinogen-bind-
ing mutant, ClfB Q235A, were still able to cause aggregation
by a complement-dependent mechanism. Both mechanisms of
platelet aggregation required specific anti-ClfB antibodies to
cross-link to the platelet FcRIIa receptor and trigger activa-
tion. The two mechanisms have similar lag times, and it is
feasible that both contribute to the overall activation and ag-
gregation caused by ClfB.
ACKNOWLEDGMENT
We acknowledge support from the Health Research Board of Ire-
land (RPO09/2002).
REFERENCES
1. Asheshov, E. H. 1966. Loss of antibiotic resistance in Staphylococcus aureus
resulting from growth at high temperature. J. Gen. Microbiol. 42:403–410.
2. Calvete, J. J. 1995. On the structure and function of platelet integrin alpha
IIb beta 3, the fibrinogen receptor. Proc. Soc. Exp. Biol Med. 208:346–360.
3. Calvete, J. J. 1999. Platelet integrin GPIIb/IIIa: structure-function correla-
tions. An update and lessons from other integrins. Proc. Soc. Exp. Biol Med.
222:29–38.
4. de Ruyter, P. G., O. P. Kuipers, M. M. Beerthuyzen, I. van Alen-Boerrigter,
and W. M. de Vos. 1996. Functional analysis of promoters in the nisin gene
cluster of Lactococcus lactis. J. Bacteriol. 178:3434–3439.
5. de Ruyter, P. G., O. P. Kuipers, and W. M. de Vos. 1996. Controlled gene
expression systems for Lactococcus lactis with the food-grade inducer nisin.
Appl. Environ. Microbiol. 62:3662–3667.
6. Doolittle, R. F. 1984. Fibrinogen and fibrin. Annu. Rev. Biochem. 53:195–
229.
7. Duthie, E. S., and L. L. Lorenz. 1952. Staphylococcal coagulase; mode of
action and antigenicity. J. Gen. Microbiol. 6:95–107.
8. Entenza, J. M., T. J. Foster, D. Ni Eidhin, P. Vaudaux, P. Francioli, and P.
Moreillon. 2000. Contribution of clumping factor B to pathogenesis of ex-
perimental endocarditis due to Staphylococcus aureus. Infect. Immun. 68:
5443–5446.
9. Farrell, D. H., P. Thiagarajan, D. W. Chung, and E. W. Davie. 1992. Role of
fibrinogen alpha and gamma chain sites in platelet aggregation. Proc. Natl.
Acad. Sci. USA 89:10729–10732.
10. Fitzgerald, J. R., T. J. Foster, and D. Cox. 2006. The interaction of bacterial
pathogens with platelets. Nat. Rev. Microbiol. 4:445–457.
11. Fitzgerald, J. R., A. Loughman, F. Keane, M. Brennan, M. Knobel, J.
Higgins, L. Visai, P. Speziale, D. Cox, and T. J. Foster. 2006. Fibronectin-
binding proteins of Staphylococcus aureus mediate activation of human
platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and
IgG binding to the FcgammaRIIa receptor. Mol. Microbiol. 59:212–230.
12. Ford, I., C. W. Douglas, D. Cox, D. G. Rees, J. Heath, and F. E. Preston.
1997. The role of immunoglobulin G and fibrinogen in platelet aggregation
by Streptococcus sanguis. Br. J. Haematol. 97:737–746.
13. Ford, I., C. W. Douglas, J. Heath, C. Rees, and F. E. Preston. 1996. Evidence
for the involvement of complement proteins in platelet aggregation by Strep-
tococcus sanguis NCTC 7863. Br. J. Haematol. 94:729–739.
14. Grundmeier, M., M. Hussain, P. Becker, C. Heilmann, G. Peters, and B.
Sinha. 2004. Truncation of fibronectin-binding proteins in Staphylococcus
aureus strain Newman leads to deficient adherence and host cell invasion due
to loss of the cell wall anchor function. Infect. Immun. 72:7155–7163.
15. Hartford, O., P. Francois, P. Vaudaux, and T. J. Foster. 1997. The dipeptide
repeat region of the fibrinogen-binding protein (clumping factor) is required
for functional expression of the fibrinogen-binding domain on the Staphy-
lococcus aureus cell surface. Mol. Microbiol. 25:1065–1076.
16. Herrick, S., O. Blanc-Brude, A. Gray, and G. Laurent. 1999. Fibrinogen. Int.
J. Biochem. Cell. Biol. 31:741–746.
17. Jackson, S. P., W. S. Nesbitt, and S. Kulkarni. 2003. Signaling events un-
derlying thrombus formation. J. Thromb. Haemost. 1:1602–1612.
18. Loughman, A., J. R. Fitzgerald, M. P. Brennan, J. Higgins, R. Downer, D.
Cox, and T. J. Foster. 2005. Roles for fibrinogen, immunoglobulin and
complement in platelet activation promoted by Staphylococcus aureus
clumping factor A. Mol. Microbiol. 57:804–818.
3342 MIAJLOVIC ET AL. INFECT. IMMUN.
19. McAleese, F. M., E. J. Walsh, M. Sieprawska, J. Potempa, and T. J. Foster.
2001. Loss of clumping factor B fibrinogen binding activity by Staphylococcus
aureus involves cessation of transcription, shedding and cleavage by metal-
loprotease. J. Biol. Chem. 276:29969–29978.
20. McDevitt, D., P. Vaudaux, and T. J. Foster. 1992. Genetic evidence that
bound coagulase of Staphylococcus aureus is not clumping factor. Infect.
Immun. 60:1514–1523.
21. Moreillon, P., and Y. A. Que. 2004. Infective endocarditis. Lancet 363:139–
149.
22. Ni Eidhin, D., S. Perkins, P. Francois, P. Vaudaux, M. Hook, and T. J.
Foster. 1998. Clumping factor B (ClfB), a new surface-located fibrinogen-
binding adhesin of Staphylococcus aureus. Mol. Microbiol. 30:245–257.
23. O’Brien, L., S. W. Kerrigan, G. Kaw, M. Hogan, J. Penades, D. Litt, D. J.
Fitzgerald, T. J. Foster, and D. Cox. 2002. Multiple mechanisms for the
activation of human platelet aggregation by Staphylococcus aureus: roles for
the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE
and protein A. Mol. Microbiol. 44:1033–1044.
24. O’Brien, L. M., E. J. Walsh, R. C. Massey, S. J. Peacock, and T. J. Foster.
2002. Staphylococcus aureus clumping factor B (ClfB) promotes adherence
to human type I cytokeratin 10: implications for nasal colonization. Cell.
Microbiol. 4:759–770.
25. Perkins, S., E. J. Walsh, C. C. Deivanayagam, S. V. Narayana, T. J. Foster,
and M. Hook. 2001. Structural organization of the fibrinogen-binding region
of the clumping factor B MSCRAMM of Staphylococcus aureus. J. Biol.
Chem. 276:44721–44728.
26. Ponnuraj, K., M. G. Bowden, S. Davis, S. Gurusiddappa, D. Moore, D. Choe,
Y. Xu, M. Hook, and S. V. Narayana. 2003. A “dock, lock, and latch”
structural model for a staphylococcal adhesin binding to fibrinogen. Cell
115:217–228.
27. Que, Y. A., J. A. Haefliger, L. Piroth, P. Francois, E. Widmer, J. M. Entenza,
B. Sinha, M. Herrmann, P. Francioli, P. Vaudaux, and P. Moreillon. 2005.
Fibrinogen and fibronectin binding cooperate for valve infection and inva-
sion in Staphylococcus aureus experimental endocarditis. J. Exp. Med. 201:
1627–1635.
28. Roche, F. M., R. Massey, S. J. Peacock, N. P. Day, L. Visai, P. Speziale, A.
Lam, M. Pallen, and T. J. Foster. 2003. Characterization of novel LPXTG-
containing proteins of Staphylococcus aureus identified from genome se-
quences. Microbiology 149:643–654.
29. Rosado, J. A., E. M. Meijer, K. Hamulyak, I. Novakova, J. W. Heemskerk,
and S. O. Sage. 2001. Fibrinogen binding to the integrin alpha(IIb)beta(3)
modulates store-mediated calcium entry in human platelets. Blood 97:2648–
2656.
30. Schaffer, A. C., R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A.
Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, T. Foster, and
J. C. Lee. 2006. Immunization with Staphylococcus aureus clumping factor B,
a major determinant in nasal carriage, reduces nasal colonization in a murine
model. Infect. Immun. 74:2145–2153.
31. Sullam, P. M., A. S. Bayer, W. M. Foss, and A. L. Cheung. 1996. Diminished
platelet binding in vitro by Staphylococcus aureus is associated with reduced
virulence in a rabbit model of infective endocarditis. Infect. Immun. 64:4915–
4921.
32. Tsurupa, G., L. Tsonev, and L. Medved. 2002. Structural organization of the
fibrin(ogen) alpha C-domain. Biochemistry 41:6449–6459.
33. Walsh, E. J., L. M. O’Brien, X. Liang, M. Hook, and T. J. Foster. 2004.
Clumping factor B, a fibrinogen-binding MSCRAMM (microbial surface
components recognizing adhesive matrix molecules) adhesin of Staphylococ-
cus aureus, also binds to the tail region of type I cytokeratin 10. J. Biol.
Chem. 279:50691–50699.
34. Wells, J. M., P. W. Wilson, and R. W. Le Page. 1993. Improved cloning
vectors and transformation procedure for Lactococcus lactis. J. Appl. Bac-
teriol. 74:629–636.
Editor: A. Camilli
VOL. 75, 2007 INTERACTION OF PLATELETS AND S. AUREUS ClfB 3343
